Promoted Companies
SORT BY:
VistaGen Therapeutics, Inc. (VSTA)
| Total paid for Promotions this month: | $240,000 | ||
| E-mails this Month: | 2 | ||
| Estimated Volume Generated: | $0 | ||
| Research Report on VSTA: | Click to see | ||
| * The information presented is based on information for Dec , 2014 | |||
VistaGen Therapeutics, Inc. (VSTA) - Tip of the Week Feb 23, 2015 08:32
VistaGen Therapeutics, Inc. (VSTA)
VistaGen is a clinical-stage biopharmaceutical company developing innovative medicine for depression and diseases and conditions involving the central nervous system (CNS). VistaGen's AV-101 is a new generation orally-available NMDA receptor glycine B-site antagonist entering Phase 2 clinical development for Major Depressive Disorder. VistaGen is also leveraging its proprietary pluripotent stem
...read more
| Promoter: | Tip.us | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VSTA |
$240,000 15,250 restricted trading shares |
UNKNOWN |
| Max Profit: 0.00 % | Gain at close: Pending |
VistaGen Therapeutics, Inc. (VSTA) - Tip of the Week Dec 15, 2014 08:32
VistaGen Therapeutics, Inc. (VSTA)
VistaGen is a clinical-stage biopharmaceutical company developing innovative medicine for depression, cancer and diseases and conditions involving the central nervous system. VistaGen's lead drug candidate, AV-101, is a novel, potent, oral NMDAR glycineB-site antagonist entering Phase 2 clinical development focused on depression.
View The Full Company Profile
Read Featured AV-101 Article
VSTA: MissionIR received
...read more
| Promoter: | Tip.us | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VSTA |
$240,000 15,250 restricted trading shares |
UNKNOWN |
| Max Profit: 0.00 % | Gain at close: Pending |
The Mission Report - Exclusively from MissionIR Apr 17, 2013 08:31
The MissionIR Report - Mid-April 2013
In-depth analysis, timely updates, latest market news
Latest Edition
Take a closer look at the companies that caught our attention this week as well as top market news. Newsletter.MissionIR.com
Stay Informed
During the week we post regular articles on our blog, featuring the latest small-cap information. Blog.MissionIR.com
Ones
...read more
| Promoter: | MissionIR | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VSTA |
$240,000 305,000 restricted trading shares 25,000 3-year warrants to purchase shares of VSTA Common Stock |
UNKNOWN |
| Max Profit: 0.00 % | Gain at close: Pending |
The QualityStocks Weekly Newsletter---PSSSSST...Keep an Eye on... Feb 03, 2013 18:01
Blog Video Market Basics Quotes & News Clients Partners About Us Contact Us
The latest from QualityStocks - The QualityStocks Weekly
Our Pick of the Week VistaGen Therapeutics, Inc. (VSTA)
Weekly.QualityStocks.net
The QualityStocks Weekly Newsletter
...read more
| Promoter: | QualityStocks | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VSTA | No compensation | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: Pending |
The QualityStocks Weekly Newsletter---PSSSSST...Keep an Eye on... Dec 16, 2012 18:02
Blog Video Market Basics Quotes & News Clients Partners About Us Contact Us
The latest from QualityStocks - The QualityStocks Weekly
Our Pick of the Week VistaGen Therapeutics, Inc. (VSTA)
Weekly.QualityStocks.net
The QualityStocks Weekly Newsletter
...read more
| Promoter: | QualityStocks | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| VSTA | No compensation | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: Pending |